Increased antitumor efficacy by the combined administration of swainsonine and cisplatin in vivo

Santos, Felipe M; Latorre, Andréia Oliveira; Hueza, Isis Machado; Sanches, Daniel Soares; Lippi, Luciana Lucinio; Gardner, Dale R.; Spinosa, Helenice de Souza

doi:10.1016/j.phymed.2011.06.005

Cited by 38 publications

(30 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The impaired peritoneal lymphatic drainage by tumor cells (Fastaia and Dumont 1976), the mechanic pressure that is exerted by the progressive increase in ascitic fluid, intraperitoneal hemorrhage and endotoxemia represent additional consequences of Ehrlich ascitic tumor development, which result in the death of the affected animals (Hartveit 1965;Mayer 1966). The aggressiveness of the Ehrlich tumor and its rapid growth make it a good model to investigate the possible synergistic effects of anticancer therapies using different mechanisms of action, as verified in a recent study that was conducted by Santos et al (2011), in which treatment with a plant compound was analyzed in combination with the chemotherapeutic drug, cisplatin. In our study, this model also permitted the assessment of whether MI and CY cause any interactions and/or reduce tumor development.…”

Section: Discussionmentioning

confidence: 94%

Mimosine and cyclophosphamide: a potential new combination therapy used to prevent tumor development

Dipe

Gotardo

Haraguchi³

et al. 2012

Braz. arch. biol. technol.

View full text Add to dashboard Cite

The effects of mimosine (MI), which is an amino acid that is derived from Leucaena leucocephala, were evaluated on the growth of ascitic Ehrlich tumors, and the effects of the combination treatment of MI and cyclophosphamide (CY) on tumor growth were also assessed. Mice were divided into groups that received the following treatments over the course of 20 days: phosphate buffer solution (CO), MI, Ehrlich cells (E), E plus CY (EC), E plus MI (EM) and E plus MI and CY (EMC). No signs of toxicity were detected in the mice from the MI group. The mice from the EMC group showed reductions in body weights when compared with those from the E group. The animals from the EC, EM and EMC groups showed reductions in ascitic volume

show abstract

Section: Discussionmentioning

confidence: 94%

Mimosine and cyclophosphamide: a potential new combination therapy used to prevent tumor development

Dipe

Gotardo

Haraguchi³

et al. 2012

Braz. arch. biol. technol.

View full text Add to dashboard Cite

show abstract

“…Recently, numerous studies have suggested through the expression changes of apoptosis-related genes in vivo that swainsonine has potential for treating glioma and gastric carcinoma through the mechanism of induced apoptosis. Additionally, initial clinical research has confirmed a clear curative effect against pate malignant tumor and chest and abdominal lymphangioma (14)(15)(16). Evidence indicates that swainsonine is a potent anticancer agent and the anticancer action of swainsonine may result from the co-operation of a number of pathways.…”

Section: Discussionmentioning

confidence: 99%

“…Swainsonine, a new class of compounds that display a wide range of pharmacological effects, has been under extensive research to examine its potential anticancer and therapeutic biological activities. A number of swainsonine-related studies confirmed that swainsonine may inhibit growth and induce apoptosis in tumor cells (14)(15)(16). However, the detailed mechanism underlying the use of swainsonine as an anticancer drug, especially through inhibition of NK-κB activation, remains unknown.…”

Section: Introductionmentioning

confidence: 99%

Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo

et al. 2012

View full text Add to dashboard Cite

Abstract. Swainsonine, an extract from Astragalus membranaceus, exhibits broad inhibition of growth and pro-apoptotic activity in a number of tumor types. However, the underlying mechanism involved remains unclear. To investigate the effects and mechanisms of swainsonine on hepatocellular carcinoma (HCC), we performed experiments on HepG2, SMCC7721, Huh7 and MHCC97-H human hepatoma and HL-7702 human hepatocyte cells. We observed that swainsonine significantly inhibited the viability of human hepatoma cells in a dose-and time-dependent manner, but did not affect human hepatocytes. Due to their highly proliferative and tumorigenic nature, we selected MHCC97-H cells as a model system to examine. Swainsonine significantly inhibited MHCC97-H cell growth by causing cell cycle arrest at the G0/G1 phase and the induction of apoptosis. Blockage of G0/G1 phase was accompanied by a decrease in cyclins (D1 and E) and cyclin-dependent kinases (Cdk2 and Cdk4) and an increase in the Cdk inhibitors p21 and p27. Furthermore, swainsonine enhanced the apoptosis of MHCC97-H cells with the induction of the upregulation of Bax and the downregulation of Bcl-2, whereas the expressionof Fas and Fas-L remained almost unchanged. These changes were accompanied by the enhanced cytoplasmic accumulation of nuclear factor κB (NF-κB) with a concomitant decrease in the nuclear fraction. Importantly, swainsonine also potentiated the cytotoxic effects of paclitaxel in vitro and in vivo, in part, by restricting the paclitaxel-induced nuclear accumulation of NF-κB. Taken together, these results suggest that swainsonine may be an important agent against HCC via directly inhibiting HCC cell growth and enhancing the responsiveness of HCC cells to paclitaxel.

show abstract

“…Similarly, in a study performed by Schneider et al (2009) pterostilbene produced synergistic effect when combined with IP6. Santos et al (2011) demonstrated that swainsonine, found in astragalus lentiginosus, enhanced the antitumor effectiveness when combined with cisplatin, leading to a 116% survival increase. The data presented in this study demonstrated that combination treatment with both AI and pterostilbene produces synergistic growth inhibition compared with either treatment alone.…”

Section: Discussionmentioning

confidence: 99%

Enhanced Antitumor Efficacy with Combined Administration of Astragalus and Pterostilbene for Melanoma

Huang¹,

Zhang²,

Wang³

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Astragalus, a commonly used traditional Chinese medicine, has exhibited antitumor actions in patients. In this study, in vitro and in vivo antitumor effects of astragalus and synergistic antitumor efficacy in combination with pterostilbene were investigated. Melanoma cells were treated with pterostilbene (Pt), graduated doses of astragalus injection (AI), or these in combination. Cell viability was measured using a MTT assay. Released nucleosomes and caspase activity were measured using enzyme-linked immunosorbent assay. Growth inhibition in vitro and in vivo was also assessed. Analysis of variance and t tests were used for statistical analysis. Significant reduction (p<0.05) in cellular proliferation were observed with AI and AI-Pt in a time-and concentration-dependent manner. Apoptosis and caspase-3/7 activity were significantly increased by AI and AI-Pt treatment (p<0.05). In vivo, AI inhibited melanoma tumor growth, with inhibition rates ranging from 36.5 to 62.3%, by inducing apoptosis via up-regulation Bax expression and the Bax/Bcl-2 ratio and down-regulating Bcl-2 expression. AI significantly inhibits the growth of melanoma in vitro and in vivo by inducing apoptosis. These data suggest that combined treatment of astragalus with pterostilbene enhances antitumor efficacy.

show abstract

Increased antitumor efficacy by the combined administration of swainsonine and cisplatin in vivo

Cited by 38 publications

References 19 publications

Mimosine and cyclophosphamide: a potential new combination therapy used to prevent tumor development

Mimosine and cyclophosphamide: a potential new combination therapy used to prevent tumor development

Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo

Enhanced Antitumor Efficacy with Combined Administration of Astragalus and Pterostilbene for Melanoma

Contact Info

Product

Resources

About